Literature DB >> 7890550

[Severe oropharyngeal angioedema caused by ACE inhibitor. A case report].

F Waldfahrer1, A Leuwer, J Krause, H Iro.   

Abstract

Inhibitors of angiotensin converting enzyme (ACE) are suspected of inducing angioedemas in up to 0.2% of all patients. These angioedemas are mainly localized in the upper airways and therefore can cause severe airway obstruction and even death due to suffocation. We report the case of a 64-year-old man, who underwent emergency tracheotomy because of severe angioedema of the larynx, which was refractory to pharmacological treatment. We conclude that patients with ACE inhibitor-induced angioedemas should be observed by monitoring in an intensive care unit to ensure the possibility of early intubation, because conventional antiallergic-antiedematous therapy by histamine-receptor antagonists and corticosteroids is an insufficient, unreliable form of therapy in severe cases. Especially otolaryngologists should know about this uncommon potentially life-threatening side-effect of ACE inhibitors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7890550

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  4 in total

1.  [ACE inhibitor-induced angioedema in the head and neck region. A matter of time?].

Authors:  M Bas; G Kojda; H Bier; T K Hoffmann
Journal:  HNO       Date:  2004-10       Impact factor: 1.284

2.  [Life-threatening swelling of the tongue in antihypertensive therapy with ACE inhibitors].

Authors:  A Brandes; R Bschorer; G Gehrke; G Kessler; R Schmelzle
Journal:  Mund Kiefer Gesichtschir       Date:  1997-02

3.  [Chronic hyperplastic laryngitis following treatment of hypertension with angiotensin converting enzyme-inhibitor].

Authors:  M Fuchs; M Bücheler
Journal:  HNO       Date:  2004-11       Impact factor: 1.284

Review 4.  ACE inhibitor-induced angioedema. Incidence, prevention and management.

Authors:  W Vleeming; J G van Amsterdam; B H Stricker; D J de Wildt
Journal:  Drug Saf       Date:  1998-03       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.